Accelerated neurodegeneration through chaperone-mediated oligomerization of tau

Laura J. Blair, Bryce A. Nordhues, Shannon E. Hill, K. Matthew Scaglione, John C. O'Leary, Sarah N. Fontaine, Leonid Breydo, Bo Zhang, Pengfei Li, Li Wang, Carl Cotman, Henry L. Paulson, Martin Muschol, Vladimir N. Uversky, Torsten Klengel, Elisabeth B. Binder, Rakez Kayed, Todd E. Golde, Nicole Berchtold, Chad A. Dickey

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Aggregation of tau protein in the brain is associated with a class of neurodegenerative diseases known as tauopathies. FK506 binding protein 51 kDa (FKBP51, encoded by FKBP5) forms a mature chaperone complex with Hsp90 that prevents tau degradation. In this study, we have shown that tau levels are reduced throughout the brains of Fkbp5-/- mice. Recombinant FKBP51 and Hsp90 synergized to block tau clearance through the proteasome, resulting in tau oligomerization. Overexpression of FKBP51 in a tau transgenic mouse model revealed that FKBP51 preserved the species of tau that have been linked to Alzheimer's disease (AD) pathogenesis, blocked amyloid formation, and decreased tangle load in the brain. Alterations in tau turnover and aggregate structure corresponded with enhanced neurotoxicity in mice. In human brains, FKBP51 levels increased relative to age and AD, corresponding with demethylation of the regulatory regions in the FKBP5 gene. We also found that higher FKBP51 levels were associated with AD progression. Our data support a model in which age-associated increases in FKBP51 levels and its interaction with Hsp90 promote neurotoxic tau accumulation. Strategies aimed at attenuating FKBP51 levels or its interaction with Hsp90 have the potential to be therapeutically relevant for AD and other tauopathies.

Original languageEnglish (US)
Pages (from-to)4158-4169
Number of pages12
JournalJournal of Clinical Investigation
Volume123
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Alzheimer Disease
Tauopathies
Brain
Tacrolimus Binding Proteins
tau Proteins
Nucleic Acid Regulatory Sequences
Proteasome Endopeptidase Complex
Amyloid
Neurodegenerative Diseases
Transgenic Mice
Disease Progression
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Blair, L. J., Nordhues, B. A., Hill, S. E., Scaglione, K. M., O'Leary, J. C., Fontaine, S. N., ... Dickey, C. A. (2013). Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. Journal of Clinical Investigation, 123(10), 4158-4169. https://doi.org/10.1172/JCI69003

Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. / Blair, Laura J.; Nordhues, Bryce A.; Hill, Shannon E.; Scaglione, K. Matthew; O'Leary, John C.; Fontaine, Sarah N.; Breydo, Leonid; Zhang, Bo; Li, Pengfei; Wang, Li; Cotman, Carl; Paulson, Henry L.; Muschol, Martin; Uversky, Vladimir N.; Klengel, Torsten; Binder, Elisabeth B.; Kayed, Rakez; Golde, Todd E.; Berchtold, Nicole; Dickey, Chad A.

In: Journal of Clinical Investigation, Vol. 123, No. 10, 01.10.2013, p. 4158-4169.

Research output: Contribution to journalArticle

Blair, LJ, Nordhues, BA, Hill, SE, Scaglione, KM, O'Leary, JC, Fontaine, SN, Breydo, L, Zhang, B, Li, P, Wang, L, Cotman, C, Paulson, HL, Muschol, M, Uversky, VN, Klengel, T, Binder, EB, Kayed, R, Golde, TE, Berchtold, N & Dickey, CA 2013, 'Accelerated neurodegeneration through chaperone-mediated oligomerization of tau', Journal of Clinical Investigation, vol. 123, no. 10, pp. 4158-4169. https://doi.org/10.1172/JCI69003
Blair LJ, Nordhues BA, Hill SE, Scaglione KM, O'Leary JC, Fontaine SN et al. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. Journal of Clinical Investigation. 2013 Oct 1;123(10):4158-4169. https://doi.org/10.1172/JCI69003
Blair, Laura J. ; Nordhues, Bryce A. ; Hill, Shannon E. ; Scaglione, K. Matthew ; O'Leary, John C. ; Fontaine, Sarah N. ; Breydo, Leonid ; Zhang, Bo ; Li, Pengfei ; Wang, Li ; Cotman, Carl ; Paulson, Henry L. ; Muschol, Martin ; Uversky, Vladimir N. ; Klengel, Torsten ; Binder, Elisabeth B. ; Kayed, Rakez ; Golde, Todd E. ; Berchtold, Nicole ; Dickey, Chad A. / Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. In: Journal of Clinical Investigation. 2013 ; Vol. 123, No. 10. pp. 4158-4169.
@article{318c52d9e4444db68fadf884b9248b2a,
title = "Accelerated neurodegeneration through chaperone-mediated oligomerization of tau",
abstract = "Aggregation of tau protein in the brain is associated with a class of neurodegenerative diseases known as tauopathies. FK506 binding protein 51 kDa (FKBP51, encoded by FKBP5) forms a mature chaperone complex with Hsp90 that prevents tau degradation. In this study, we have shown that tau levels are reduced throughout the brains of Fkbp5-/- mice. Recombinant FKBP51 and Hsp90 synergized to block tau clearance through the proteasome, resulting in tau oligomerization. Overexpression of FKBP51 in a tau transgenic mouse model revealed that FKBP51 preserved the species of tau that have been linked to Alzheimer's disease (AD) pathogenesis, blocked amyloid formation, and decreased tangle load in the brain. Alterations in tau turnover and aggregate structure corresponded with enhanced neurotoxicity in mice. In human brains, FKBP51 levels increased relative to age and AD, corresponding with demethylation of the regulatory regions in the FKBP5 gene. We also found that higher FKBP51 levels were associated with AD progression. Our data support a model in which age-associated increases in FKBP51 levels and its interaction with Hsp90 promote neurotoxic tau accumulation. Strategies aimed at attenuating FKBP51 levels or its interaction with Hsp90 have the potential to be therapeutically relevant for AD and other tauopathies.",
author = "Blair, {Laura J.} and Nordhues, {Bryce A.} and Hill, {Shannon E.} and Scaglione, {K. Matthew} and O'Leary, {John C.} and Fontaine, {Sarah N.} and Leonid Breydo and Bo Zhang and Pengfei Li and Li Wang and Carl Cotman and Paulson, {Henry L.} and Martin Muschol and Uversky, {Vladimir N.} and Torsten Klengel and Binder, {Elisabeth B.} and Rakez Kayed and Golde, {Todd E.} and Nicole Berchtold and Dickey, {Chad A.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1172/JCI69003",
language = "English (US)",
volume = "123",
pages = "4158--4169",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "10",

}

TY - JOUR

T1 - Accelerated neurodegeneration through chaperone-mediated oligomerization of tau

AU - Blair, Laura J.

AU - Nordhues, Bryce A.

AU - Hill, Shannon E.

AU - Scaglione, K. Matthew

AU - O'Leary, John C.

AU - Fontaine, Sarah N.

AU - Breydo, Leonid

AU - Zhang, Bo

AU - Li, Pengfei

AU - Wang, Li

AU - Cotman, Carl

AU - Paulson, Henry L.

AU - Muschol, Martin

AU - Uversky, Vladimir N.

AU - Klengel, Torsten

AU - Binder, Elisabeth B.

AU - Kayed, Rakez

AU - Golde, Todd E.

AU - Berchtold, Nicole

AU - Dickey, Chad A.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Aggregation of tau protein in the brain is associated with a class of neurodegenerative diseases known as tauopathies. FK506 binding protein 51 kDa (FKBP51, encoded by FKBP5) forms a mature chaperone complex with Hsp90 that prevents tau degradation. In this study, we have shown that tau levels are reduced throughout the brains of Fkbp5-/- mice. Recombinant FKBP51 and Hsp90 synergized to block tau clearance through the proteasome, resulting in tau oligomerization. Overexpression of FKBP51 in a tau transgenic mouse model revealed that FKBP51 preserved the species of tau that have been linked to Alzheimer's disease (AD) pathogenesis, blocked amyloid formation, and decreased tangle load in the brain. Alterations in tau turnover and aggregate structure corresponded with enhanced neurotoxicity in mice. In human brains, FKBP51 levels increased relative to age and AD, corresponding with demethylation of the regulatory regions in the FKBP5 gene. We also found that higher FKBP51 levels were associated with AD progression. Our data support a model in which age-associated increases in FKBP51 levels and its interaction with Hsp90 promote neurotoxic tau accumulation. Strategies aimed at attenuating FKBP51 levels or its interaction with Hsp90 have the potential to be therapeutically relevant for AD and other tauopathies.

AB - Aggregation of tau protein in the brain is associated with a class of neurodegenerative diseases known as tauopathies. FK506 binding protein 51 kDa (FKBP51, encoded by FKBP5) forms a mature chaperone complex with Hsp90 that prevents tau degradation. In this study, we have shown that tau levels are reduced throughout the brains of Fkbp5-/- mice. Recombinant FKBP51 and Hsp90 synergized to block tau clearance through the proteasome, resulting in tau oligomerization. Overexpression of FKBP51 in a tau transgenic mouse model revealed that FKBP51 preserved the species of tau that have been linked to Alzheimer's disease (AD) pathogenesis, blocked amyloid formation, and decreased tangle load in the brain. Alterations in tau turnover and aggregate structure corresponded with enhanced neurotoxicity in mice. In human brains, FKBP51 levels increased relative to age and AD, corresponding with demethylation of the regulatory regions in the FKBP5 gene. We also found that higher FKBP51 levels were associated with AD progression. Our data support a model in which age-associated increases in FKBP51 levels and its interaction with Hsp90 promote neurotoxic tau accumulation. Strategies aimed at attenuating FKBP51 levels or its interaction with Hsp90 have the potential to be therapeutically relevant for AD and other tauopathies.

UR - http://www.scopus.com/inward/record.url?scp=84885054226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885054226&partnerID=8YFLogxK

U2 - 10.1172/JCI69003

DO - 10.1172/JCI69003

M3 - Article

VL - 123

SP - 4158

EP - 4169

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 10

ER -